Feasibility study of using high‐throughput drug sensitivity testing to target recurrent glioblastoma stem cells for individualized treatment. Issue 1 (30th December 2019)

• Record Type: Journal Article
• Authors: Skaga, Erlend; Kulesskiy, Evgeny; Brynjulvsen, Marit; Sandberg, Cecilie J.; Potdar, Swapnil; Langmoen, Iver A.; Laakso, Aki; Gaál‐Paavola, Emília; Perola, Markus; Wennerberg, Krister; Vik‐Mo, Einar O.
• Is Part Of: Clinical and translational medicine. Volume 8:Issue 1(2019)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-12-30
• Subjects: Glioblastoma -- Recurrent glioblastoma -- Glioblastoma stem cells -- High‐throughput drug screening -- Drug sensitivity and resistance testing -- Individualized medicine -- Drug sensitivity; Clinical medicine -- Periodicals; Medicine, Experimental -- Periodicals; Medical innovations -- Periodicals; Molecular biology -- Periodicals; Pathology, Molecular -- Periodicals; 616.027
• DOI: 10.1186/s40169-019-0253-6
• Languages: English
• ISSNs: 2001-1326

Abstract

Abstract: Background: Despite the well described heterogeneity in glioblastoma (GBM), treatment is standardized, and clinical trials investigate treatment effects at population level. Genomics‐driven oncology for stratified treatments allow clinical decision making in only a small minority of screened patients. Addressing tumor heterogeneity, we aimed to establish a clinical translational protocol in recurrent GBM (recGBM) utilizing autologous glioblastoma stem cell (GSC) cultures and automated high‐throughput drug sensitivity and resistance testing (DSRT) for individualized treatment within the time available for clinical application. Results: From ten patients undergoing surgery for recGBM, we established individual cell cultures and characterized the GSCs by functional assays. 7/10 GSC cultures could be serially expanded. The individual GSCs displayed intertumoral differences in their proliferative capacity, expression of stem cell markers and variation in their in vitro and in vivo morphology. We defined a time frame of 10 weeks from surgery to complete the entire pre‐clinical work‐up; establish individualized GSC cultures, evaluate drug sensitivity patterns of 525 anticancer drugs, and identify options for individualized treatment. Within the time frame for clinical translation 5/7 cultures reached sufficient cell yield for complete drug screening. The DSRT revealed significant intertumoral heterogeneity to anticancer drugs (p < 0.0001). Using curated reference databases of drug sensitivity in GBM and healthy bone marrow cells, we identified individualized treatment options in all patients. Individualized treatment options could be selected from FDA‐approved drugs from a variety of different drug classes in all cases. Conclusions: In recGBM, GSC cultures could successfully be established in the majority of patients. The individual cultures displayed intertumoral heterogeneity in their in vitro and in vivo behavior. Within a time frame for clinical application, we could perform DSRT in 50% of recGBM patients. The DSRT revealed a remarkable intertumoral heterogeneity in sensitivity to anticancer drugs in recGBM that could allow tailored therapeutic options for functional precision medicine.